Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA)

Sleep disordered breathing (SDB) is highly prevalent, with a male to female predominance of two to one, and is more common in middle-aged and elderly subjects [1]. Affected patients often present with comorbidities such as obesity, cardiovascular disease (systemic hypertension, heart failure, atrial fibrillation) and diabetes mellitus type II [2]. The strong overlap between the profile for SDB patients and the identified risk factors for adverse outcomes of coronavirus disease 2019 (COVID-19) infection, which include age, male sex and cardiometabolic comorbidity [3], suggest that SDB patients may benefit from effective therapy if confronted with COVID-19 infection [4].

Source: European Respiratory Journal - June 17, 2020 Category: Respiratory Medicine Authors: Grote, L., McNicholas, W. T., Hedner, J., on behalf of the ESADA collaborators Tags: Original Articles: Research letters Source Type: research